|
rs397517094
|
|
AAA |
0.700 |
GeneticVariation |
CLINVAR |
|
|
|
|
rs397517098
|
|
T |
0.700 |
GeneticVariation |
CLINVAR |
|
|
|
|
rs397517111
|
|
CGGGTTG |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs121913428
|
|
C |
0.740 |
CausalMutation |
CLINVAR |
"Effectiveness of tyrosine kinase inhibitors on ""uncommon"" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer."
|
21531810 |
2011 |
|
rs121913444
|
|
A |
0.750 |
CausalMutation |
CLINVAR |
"EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib."
|
15329413 |
2004 |
|
rs28929495
|
|
T |
0.750 |
CausalMutation |
CLINVAR |
"EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib."
|
15329413 |
2004 |
|
rs121913428
|
|
C |
0.740 |
CausalMutation |
CLINVAR |
"EGF receptor gene mutations are common in lung cancers from ""never smokers"" and are associated with sensitivity of tumors to gefitinib and erlotinib."
|
15329413 |
2004 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<b>Background</b>: Approximately 50% of non-small cell lung cancer (NSCLC) patients with acquired resistance to EGFR-TKI harbor the <i>EGFR</i> mutation T790M.
|
29581791 |
2018 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
<b>Background:</b> Advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion (19 Del) and exon 21 L858R mutation (L858R) might be distinct diseases.
|
28819384 |
2017 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
<b>Background:</b> Advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion (19 Del) and exon 21 L858R mutation (L858R) might be distinct diseases.
|
28819384 |
2017 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
<b>Background:</b> Advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion (19 Del) and exon 21 L858R mutation (L858R) might be distinct diseases.
|
28819384 |
2017 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
<b>Methods</b> We retrospectively analyzed the clinical outcomes of 75 consecutive advanced NSCLC patients with EGFR-TKI sensitive mutations (exon 19 deletion or exon 21 L858R) received first-line gefitinib or erlotinib therapy according to weight loss status at presentation in our single center.
|
29483958 |
2018 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
<b>Methods</b> We retrospectively analyzed the clinical outcomes of 75 consecutive advanced NSCLC patients with EGFR-TKI sensitive mutations (exon 19 deletion or exon 21 L858R) received first-line gefitinib or erlotinib therapy according to weight loss status at presentation in our single center.
|
29483958 |
2018 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
<b>Methods</b> We retrospectively analyzed the clinical outcomes of 75 consecutive advanced NSCLC patients with EGFR-TKI sensitive mutations (exon 19 deletion or exon 21 L858R) received first-line gefitinib or erlotinib therapy according to weight loss status at presentation in our single center.
|
29483958 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<b>Purpose:</b> The third-generation <i>EGFR</i> tyrosine kinase inhibitor osimertinib is approved to treat patients with <i>EGFR</i> T790M-positive non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs.
|
29506987 |
2018 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<i>KRAS</i> and <i>EGFR</i> Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in <i>EGFR</i>.
|
30322949 |
2019 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<i>Objective:</i> ASTRIS is a large real-world, open-label, multinational clinical study of osimertinib in patients with epidermal growth factor receptor (EGFR) T790M mutation-positive advanced non-small cell lung cancer (NSCLC) who have previously received a tyrosine kinase inhibitor (TKI).
|
31581843 |
2020 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
: Our results imply that blockade of the TGF-β signaling pathway combined with continuous EGFR TKI treatment will be beneficial in preventing metastasis in patients with EGFR TKI-resistant NSCLC without the EGFR T790M resistance mutation.
|
23334091 |
2013 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) patients with L858R or exon 19 deletion mutations in epidermal growth factor receptor (EGFR) have good responses to the tyrosine kinase inhibitor (TKI), gefitinib.
|
21858220 |
2011 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) patients with L858R or exon 19 deletion mutations in epidermal growth factor receptor (EGFR) have good responses to the tyrosine kinase inhibitor (TKI), gefitinib.
|
21858220 |
2011 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) patients with L858R or exon 19 deletion mutations in epidermal growth factor receptor (EGFR) have good responses to the tyrosine kinase inhibitor (TKI), gefitinib.
|
21858220 |
2011 |
|
rs121434569
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) patients treated with small molecule EGFR inhibitors, such as gefitinib, frequently develop drug resistance due to the presence of secondary mutations like the T790M mutation on EGFR exon 20.
|
23805327 |
2013 |
|
rs397517132
|
|
|
0.100 |
GeneticVariation |
BEFREE |
NSCLC routinely tested for EGFR-mutations at Oslo University Hospital in the period February 2011-July 2013 were tested for V600E/K BRAF-mutations using a PCR-based method.
|
24552757 |
2014 |
|
rs1057519847
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) with minor mutations in the epidermal growth factor receptor (EGFR) gene, except for the common 15 base-pair deletions in exon 19 and the L858R mutation in exon 21, is rare, and only few data exist on this patient population.
|
26124334 |
2015 |
|
rs1057519848
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Non-small cell lung cancer (NSCLC) with minor mutations in the epidermal growth factor receptor (EGFR) gene, except for the common 15 base-pair deletions in exon 19 and the L858R mutation in exon 21, is rare, and only few data exist on this patient population.
|
26124334 |
2015 |